TY - JOUR
T1 - Steroid sidestep
T2 - Evading androgen ablation by abiraterone
AU - Sharifi, Nima
N1 - Publisher Copyright:
©2014 American Association for Cancer Research.
PY - 2015/3/15
Y1 - 2015/3/15
N2 - Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.
AB - Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84927666834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927666834&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-2899
DO - 10.1158/1078-0432.CCR-14-2899
M3 - Article
C2 - 25432158
AN - SCOPUS:84927666834
SN - 1078-0432
VL - 21
SP - 1240
EP - 1242
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -